Log In
BCIQ
Print this Print this
 

Sancuso, granisetron patch (SP-01)

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionTransdermal serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation
PartnerEndo International plc;
Lee's Pharmaceutical Holdings Ltd.;
LG Life Sciences Ltd.;
Menarini Group;
NewBridge Pharmaceuticals Ltd.;
Quintiles IMS Holdings Inc.;
Solasia Pharma K.K.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today